Vanderbilt researchers suggest that to reduce treatment-related regret for men with localized prostate cancer, treatment preparation should focus on shared decision-making and aligning patient expectations with treatment toxicity.

A new combination treatment showed promise in slowing the growth of castration-resistant prostate cancer in animal models, Vanderbilt researchers discovered.

An indirect comparative effectiveness study using published data suggests that the targeted therapy olaparib should be re-evaluated for treating metastatic prostate cancer.

Distinct cancer-associated fibroblasts in the prostate tumor microenvironment may influence tumor progression and could point to new therapeutic targets.

An international group of researchers including Vanderbilt epidemiologists has identified new DNA methylation biomarkers associated with prostate cancer risk.

Vanderbilt researchers have identified haplotypes, ancestral fragments of DNA, that are associated with hereditary prostate cancer (HPC) in a first-of-its-kind genomic study made possible by the study of prostate cancer patients with family histories of the disease.